Explore emerging IgA nephropathy therapies—complement and BAFF/APRIL inhibitors, targeted budesonide—and why long‑term safety data still lags. In this episode, Overcoming Access Barriers and Step-Edit ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果一些您可能无法访问的结果已被隐去。
显示无法访问的结果